Simple and Inexpensive Ebola Virus Disease Test Developed
|
By LabMedica International staff writers Posted on 21 May 2019 |

Image: A digitally colorized, transmission electron microscopic (TEM) image, which reveals some of the ultrastructural morphology displayed by an Ebola virus virion (Photo courtesy of Cynthia Goldsmith / CDC).
Ebola and Marburg viruses can cause severe bleeding and organ failure, with fatality rates reaching 90% in some outbreaks. The diseases spread through direct contact with bodily fluids of an infected person, monkey, gorilla, chimpanzee or bat.
Early symptoms of Ebola and Marburg, include fever, headache and diarrhea, and mimic more common diseases, so there's a critical need for a rapid diagnostic test. Such a test could help in efforts to limit outbreaks by quickly quarantining infected persons. But existing diagnostic tests either are inaccurate or are expensive and require extensive training to administer.
Scientists at the Loyola University Health System (Maywood, IL, USA) have generated a panel of mouse single-chain Fv-antibodies (scFvs) to filovirus glycoproteins (GPs) using cell-free ribosome display and determined their cross-reactivity profiles to all known filovirus species. Antibodies could be the key to diagnosing Ebola and Marburg viruses. An antibody is a Y-shaped protein made by the immune system. When a virus or other pathogen invades the body, antibodies mark it for the immune system to destroy.
The team used a technology called cell-free ribosome display, and generated two synthetic antibodies that bind to all six Ebola and Marburg viruses. The study involved the use of non-hazardous proteins that sit on the surface of Ebola and Marburg viruses. Because the actual viruses were not used in the study, there was no risk of infection to the scientists or the public. The antibodies, which are inexpensive to produce, potentially could be used in a simple filter paper test to detect Ebola virus and the related Marburg virus. If the filter paper turns color, the virus is present. The study was published on May 6, 2019, in the American Journal of Tropical Medicine & Hygiene.
Related Links:
Loyola University Health System
Early symptoms of Ebola and Marburg, include fever, headache and diarrhea, and mimic more common diseases, so there's a critical need for a rapid diagnostic test. Such a test could help in efforts to limit outbreaks by quickly quarantining infected persons. But existing diagnostic tests either are inaccurate or are expensive and require extensive training to administer.
Scientists at the Loyola University Health System (Maywood, IL, USA) have generated a panel of mouse single-chain Fv-antibodies (scFvs) to filovirus glycoproteins (GPs) using cell-free ribosome display and determined their cross-reactivity profiles to all known filovirus species. Antibodies could be the key to diagnosing Ebola and Marburg viruses. An antibody is a Y-shaped protein made by the immune system. When a virus or other pathogen invades the body, antibodies mark it for the immune system to destroy.
The team used a technology called cell-free ribosome display, and generated two synthetic antibodies that bind to all six Ebola and Marburg viruses. The study involved the use of non-hazardous proteins that sit on the surface of Ebola and Marburg viruses. Because the actual viruses were not used in the study, there was no risk of infection to the scientists or the public. The antibodies, which are inexpensive to produce, potentially could be used in a simple filter paper test to detect Ebola virus and the related Marburg virus. If the filter paper turns color, the virus is present. The study was published on May 6, 2019, in the American Journal of Tropical Medicine & Hygiene.
Related Links:
Loyola University Health System
Latest Microbiology News
- Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s
Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more
Composite Blood Biomarkers Enable Early Detection of Common Cancers
Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read moreHematology
view channel
Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read moreMicrobiology
view channel
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria
Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. Nearly 20 million new cases are diagnosed each year, and traditional artificial... Read more
AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
Prostate and breast cancers are among the most commonly diagnosed malignancies worldwide, and heterogeneous disease biology complicates risk stratification and treatment selection. Clinicians increasingly... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more





.jpg)

